Tucatinib authorised by UK’s MHRA for locally advanced or metastatic HER2-positive breast cancer
Seagen UK Ltd. today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA)…
Browsing: tucatinib
FDA approves tucatinib in combination with chemotherapy for patients with HER2-positive metastatic breast cancer
The U.S. Food and Drug Administration (FDA) approved tucatinib in combination with chemotherapy (trastuzumab and capecitabine)…
Adding tucatinib to drug combination extends survival for advanced HER2-positive breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing…
Tucatinib progressing in pivotal trial against HER2 breast cancer
Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of…